Theravance Study for Ulcerative Colitis

Ulcerative colitis (UC) is an inflammatory bowel disease that causes irritation, inflammation, and ulcers in the lining of your large intestine. It causes your immune system to think food, good gut bacteria, and the cells that line your colon are intruders — attacking them by mistake.

For more information about this study, download our brochure.

Who can take part in the study?

The Theravance Study for Ulcerative Colitis is a phase two randomized, double-blind, multi-dose, placebo-controlled, and parallel-group study to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis. All study-related medical procedures and tests will be provided at no cost to you.

Infusion Associates | Theravance UC Study


18+ Years

Key Inclusion and Exclusion Criteria:

Patients must be at least 18 years old at age of screening. They should also be diagnosed with moderately-to-severely active Ulcerative Colitis for at least 3 months prior to screening, and have tried one or more standard of care treatments that did not work, stopped working, or were not tolerated.

Patient Commitment Duration:

16 Months

Interested in taking part in a clinical trial?

If you are interested in taking part in one of our active clinical trials, fill out the form below and one of our team members will reach out to you with more information.

    Which trial are you interested in?



    Fast and efficient. The nurse was skilled, informative and very friendly.



    Liz F.


    Interested in Other Enrolling Clinical Trials?

    All of our studies are approved by the Food and Drug Administration (FDA). To find out more, click on the links below.